Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AVITA Medical Inc RCEL

Healthcare Biotechnology
AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile... see more

Recent & Breaking News (NDAQ:RCEL)

AVITA Medical to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide 2023 Financial Guidance

GlobeNewswire February 9, 2023

AVITA Medical Announces Management Changes and Fourth Quarter 2022 Earnings Conference Call

GlobeNewswire January 19, 2023

AVITA Medical Submits FDA PMA Application to Expand Indication to Vitiligo

GlobeNewswire December 19, 2022

AVITA Medical Announces Results of 2022 Annual Meeting of Stockholders

GlobeNewswire December 12, 2022

AVITA Medical Submits FDA PMA Supplement to Further Expand Indication to Soft Tissue Repair

GlobeNewswire December 12, 2022

AVITA Medical® to Present at the Piper Sandler 34th Annual Healthcare Conference

GlobeNewswire November 21, 2022

AVITA Medical® to Host Investor Webinar Briefing

GlobeNewswire November 16, 2022

AVITA Medical Reports Third Quarter 2022 Financial Results

GlobeNewswire November 10, 2022

AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL® System for Soft Tissue Repair

GlobeNewswire November 9, 2022

AVITA Medical Announces FDA Breakthrough Device Designations for the RECELL® System

GlobeNewswire November 3, 2022

AVITA Medical to Announce Third Quarter 2022 Financial Results

GlobeNewswire October 20, 2022

AVITA Medical Appoints Industry Leader James Corbett as Chief Executive Officer

GlobeNewswire September 28, 2022

Investor Webinar Briefing (RCEL, AVH)

Newsfile September 19, 2022

Investor Webinar Briefing

GlobeNewswire September 13, 2022

AVITA Medical Achieves Positive Topline Pivotal Trial Results for Treatment of Stable Vitiligo Using the RECELL® System

GlobeNewswire September 12, 2022

RECELL System Insurance Coverage Begins in Japan for Treatment of Acute Burns

GlobeNewswire September 1, 2022

RECELL® System Data to be Presented at the Controversies and Conversations in Laser & Cosmetic Surgery Annual Meeting

GlobeNewswire August 17, 2022

AVITA Medical Reports Second Quarter 2022 Financial Results

GlobeNewswire August 11, 2022

AVITA Medical Announces Topline Results from Pivotal Trial in Patients with Soft-Tissue Injuries using the RECELL® System

GlobeNewswire August 11, 2022

AVITA Medical to Announce Second Quarter 2022 Financial Results

GlobeNewswire July 25, 2022